Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis

Acta Psychiatrica Scandinavica

Volumn 125, Issue 1, 2012, Pages 45-53

  Dragt, S ^a   Nieman, D H ^a   Schultze Lutter, F ^b   van der Meer, F ^a   Becker, H ^a   de Haan, L ^a   Dingemans, P M ^c   Birchwood, M ^d   Patterson, P ^d   Salokangas, R K R ^e   Heinimaa, M ^e   Heinz, A ^f   Juckel, G ^g   Graf von Reventlow, H ^g   French, P ^h   Stevens, H ⁱ   Ruhrmann, S ^j   Klosterkotter J ^j   Linszen, D H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

^c Mediant   (Netherlands)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF TURKU   (Finland)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁱ GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

Age at onset; Cannabis; Prodromal; Psychosis

Indexed keywords

CANNABIS;

ADOLESCENT; ADULT; AGE; ARTICLE; CANNABIS ADDICTION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; STRUCTURED INTERVIEW;

EID: 83555176239     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2011.01763.x     Document Type: Article

References (43)

1. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994;51:273-279.
2. Hambrecht M, Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry 2000;34:468-475.
3. Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry 1996;40:1155-1163.
4. Compton MT, Kelley ME, Ramsay CE et al. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry 2009;166:1251-1257.
5. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004;184:111-117.
6. Henquet C, Murray R, Linszen DH, Van Os J, The environment and schizophrenia: the role of cannabis use. Schizophr Bull 2005;31:608-612.
7. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-328.
8. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 2007;8:885-895.
9. Konings M, Henquet C, Maharajh HD, Hutchinson G, Van Os J. Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. Acta Psychiatr Scand 2008;118:209-213.
10. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffit T. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002;325:1212-1213.
11. Veen ND, Selten JP, Van Der Tweel I, Feller WG, Hoek HW, Kahn RS. Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004;161:501-506.
12. Miettunen J, Törmänen S, Murray GK et al. Association of cannabis use with prodromal symptoms of psychosis in adolescence. Br J Psychiatry 2008;192:470-471.
13. Skinner R, Conlon L, Gibbons D, Mcdonald C. Cannabis use and nonclinical dimensions of psychosis in university students presenting to primary care. Acta Psychiatr Scand 2011;123:21-27.
14. Sevy S, Robinson DG, Napolitano B et al. Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia. Schizophr Res 2010;120:101-107.
15. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia a longitudinal study of Swedish conscript. Lancet 1987;2:1483-1486.
16. Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry 1993;163:141-149.
17. Reilly D, Didcott R, Swift W, Hall W. Long-term cannabis use: characteristics of users in Australian rural areas. Addiction 1998;93:837-846.
18. Hall W, Solowij N, Lemon J. The health and psychological consequences of cannabis use. National Drug Strategy Monograph Series (no 25). Canberra: Australian Government Publishing Service, 1994.
19. Peters BD, De Koning P, Dingemans P, Becker H, Linszen DH, De Haan L. Subjective effects of cannabis before the first psychotic episode. Aust N Z J Psychiatry 2009;43:1155-1162.
20. Dekker N, Linszen DH, De Haan L. Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology 2009;42:350-360.
21. Yung AR, Mcgorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 1996;22:353-370.
22. Klosterkötter J, Ruhrmann S, Schultze-Lutter F et al. The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry 2005;4:161-167.
23. Ruhrmann S, Schultze-Lutter F, Salokangas RKR et al. Prediction of psychosis in adolescents and young adults at high risk: results from the Prospective European Prediction of Psychosis Study (EPOS). Arch Gen Psychiatry 2010;67:241-251.
24. Mcglashan TH, Miller TJ, Woods SW, Rosen JL, Hoffman RE, Davidson L. Structured interview for prodromal syndromes (version 3.0). New Haven: PRIME Research Clinic, Yale School of Medicine, 2001.
25. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J. Schizophrenia Proneness Instrument - Adult version (SPI-A). Rome: Giovanni Fioriti.
26. Kay SR, Fiszbein A, Opler LA. The positive and negative symptom scale (PANSS). Schizophr Bull 1987;13:261-276.
27. Hall RC. Global assessment of functioning. A modified scale. Psychosomatics 1995;36:267-275.
28. Hall RC, Parks J. The modified global assessment of functioning scale: addendum. Psychosomatics 1995;36:416-417.
29. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Arlington, VA, USA: American Psychiatric Publishing, 1997.
30. Andrews G, Peters L. The psychometric properties of the Composite International Diagnostic Interview. Soc Psychiatry Psychiatr Epidemiol 1998;33:80-88.
31. Häfner H, Riecher-Rössler A, Hambrecht M et al. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr Res 1992;6:209-223.
32. Cannon-Spoor H, Potkin G, Wyatt J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 1982;8:470-484.
33. Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S, Mcgorry PD. Cannabis use is not associated with the development of psychosis in an 'ultra' high-risk group. Aust N Z J Psychiatry 2002;36:800-806.
34. Corcoran CM, Kimhy D, Stanford A et al. Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res 2008;106:286-293.
35. Dragt S, Nieman DH, Becker HE et al. Age at onset of cannabis use is associated with age at onset of high-risk symptoms for psychosis. Can J Psychiatry 2010;55:165-171.
36. Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res 2007;30:151-154.
37. Cannon TD, Cadenhead K, Cornblatt B et al. Prediction of psychosis in youth at high clinical risk. Arch Gen Psychiatry 2008;65:28-37.
38. Van Os J, Bak M, Hanssen M, Bijl RV, De Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002;156:319-327.
39. Ferdinand RF, Sondeijker F, Van Der Ende J, Selten J, Huizink A, Verhulst FC. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005;100:612-618.
40. Caspi A, Moffit TE, Cannon M et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol Psychiatry 2005;57:1117-1127.
41. Estrada G, Fatjo'-Vilas M, Muñoz MJ et al. Cannabis use and age at onset of psychosis: further evidence of interaction with COMT Val158Met polymorphism. Acta Psychiatr Scand 2011;123:1-8.
42. Brill N, Reichenberg A, Rabinowitz J et al. Accuracy of self-reported premorbid functioning in schizophrenia. Schizophr Res 2007;97:103-108.
43. Johnson TP, Mott JA. The reliability of self reported age of onset of tobacco, alcohol and illicit drug use. Addiction 2001;96:1187-1198.